<DOC>
	<DOCNO>NCT00265824</DOCNO>
	<brief_summary>PURPOSE : This randomized phase III trial study maintenance therapy bevacizumab alone induction therapy combine bevacizumab+chemotherapy see well work compare maintenance therapy bevacizumab+erlotinib alone induction therapy combine bevacizumab+chemotherapy treat patient metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Optimized Chemotherapy Followed Maintenance With Bevacizumab With Without Erlotinib Treating Patients With Metastatic Colorectal Cancer That Can Removed Surgery ( DREAM )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare Progression-free survival maintenance period ( `` Maintenance PFS '' ) patient unresectable metastatic colorectal cancer . Secondary - Compare duration disease control overall survival patient treat regimen . - Compare tolerability regimens patient . - Compare quality life patient treat regimen . - Compare occurrence secondary surgery patient treat regimen . - Compare chemotherapy-free interval response rate patient treat regimen . INDUCTION THERAPY Bevacizumab IV 30-90 minute day 1 , combine either : - modify FOLFOX7 ( IV : oxaliplatin , folinic acid , fluorouracil ) , - XELOX2 ( IV : oxaliplatin , oral capecitabine day 1 8 ) , - FOLFIRI ( IV : irinotecan , folinic acid , fluorouracil ) . Treatment repeat every 2 week . RANDOMIZATION Patients stable respond disease receive maintenance therapy bevacizumab alone bevacizumab+erlotinib MAINTENANCE THERAPY - Arm A : bevacizumab alone : bevacizumab IV 30-90 minute day 1 - Arm B : bevacizumab+erlotinib : bevacizumab IV 30-90 minute day 1 oral erlotinib daily day 1-21 . In arm , treatment bevacizumab +/- erlotinib repeat every 3 week absence disease progression unacceptable toxicity . ACCRUAL : A total 700 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>MAIN ELIGIBILITY CRITERIA Histologically proven metastatic adenocarcinoma colon rectum Documented inoperable disease ( i.e. , suitable complete carcinological surgical resection ) Measurable lesion assess CT scan MRI least one dimension ( long diameter record ) ≥ 20 mm conventional CT scan ≥ 10 mm spiral CT scan No previous therapy metastatic disease No history evidence upon physical examination CNS disease ( e.g. , nonirradiated CNS metastasis , seizure control standard medical therapy , history stroke ) unless adequately treat No exclusive bone metastasis ECOG performance status 02 WBC ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Hemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) Proteinuria &lt; 2+ dipstick OR ≤ 1 g protein 24hr urine collection Bilirubin &lt; 1.5 time ULN Alkaline phosphatase &lt; 3 time ULN No peripheral sensory neuropathy Negative pregnancy test Fertile patient must use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly , surgically sterilization ) No peripheral neuropathy ≥ grade 1 No clinically significant ( i.e . active ) cardiovascular disease No evidence bleed diathesis coagulopathy No serious , nonhealing wound , ulcer , bone fracture No significant ophthalmologic abnormality More 28 day since prior major surgical procedure open biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>chemotherapy</keyword>
</DOC>